(Q57788342)

10

object named as

Albert Hofman

0 references

author name string

Rianne MF van Schie

1

0 references

Judith AM Wessels

2

0 references

Talitha I Verhoef

3

0 references

Tom Schalekamp

4

0 references

Felix JM van der Meer

6

0 references

Frits R Rosendaal

7

0 references

Loes E Visser

8

0 references

Martina Teichert

9

0 references

Peter NM Buhre

11

0 references

Anthonius de Boer

12

0 references

Anke-Hilse Maitland-van der Zee

Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands

13

0 references

publication date

December 2012

0 references

published in

Pharmacogenomics

0 references

volume

13

0 references

issue

16

0 references

page(s)

1917-1923

0 references

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Medication use leading to emergency department visits for adverse drug events in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

The Scylla and Charybdis of oral anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Factors affecting the maintenance dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Lifestyle and diet as risk factors for overanticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Integration of genetic, clinical, and INR data to refine warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

The structure of haplotype blocks in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Determinants of disease and disability in the elderly: The Rotterdam elderly study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

A genome-wide association study of acenocoumarol maintenance dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.174